$TRX
Did You Win and Profit Over NT$130,000? Taiho Biotech (6467) Opens Public Subscription—What Should You Watch for When Applying for a Stock Lottery?
Taiho Biotech (6467), a biotech company focused on developing new-formulation drugs, will open its public subscription from 10/7 to 10/12. Based on a tentative underwriting price of NT$105.6 and an estimated over-the-counter (OTC) market price of around NT$241, winning one lot could mean a potential profit of over NT$134,000, with a return rate as high as 127%. What is a stock lottery? And how do you participate? What does Taiho Biotech (6467) do?
Taiho Biotech (6467) was established in 2010. The company mainly focuses on R&D and patent licensing for “new formulations of drugs (505(b)(2)).” It has its own developed transdermal drug delivery system (TDS) technology platform. Its core business is centered on two major dosage forms: “oral dissolving films (ODF)” designed for patients with dysphagia, and “transdermal patches (Patch)” that provide long-lasting, stable drug delivery.
Taiho’s main product lines include the world’s first antithrombotic oral dissolving film (TAH3311 / Apixaban) improved specifically for populations with swallowing disorders, chemotherapy antiemetic patches, and medications related to the central nervous system. After being listed on Taiwan’s OTC market for years, Taiho Biotech has obtained approval from the Taiwan Stock Exchange and has officially kicked off pre-listing capital increase and public underwriting procedures.
What is a stock lottery?
The official term for a stock lottery is “public subscription.” It is a mechanism for companies to raise capital by issuing new shares to the public. When a company conducts an initial public offering (IPO) or a cash capital increase after listing, regulations require that a certain proportion of shares be allocated for public subscription.
Investors must submit an application through a broker’s trading platform and, on the designated payment/settlement day, ensure there is enough money in their delivery account for the subscription amount and related handling fees. If the total number of subscribers exceeds the number of share lots available for allocation, the Taiwan Stock Exchange will conduct a computer-based random lottery to ensure the allocation mechanism is fair and transparent.
What are the risks of a stock lottery?
For most investors, the key motivation for participating is the potential spread between the “underwriting price” and the “market price.” To attract market demand, lead underwriters typically offer the underwriting price at a discount relative to the market. However, participating in the subscription requires paying an opportunity cost—the funds are frozen. On the payment day after the subscription deadline, the full subscription amount will be deducted in advance and frozen for several trading days until the refund date for unsuccessful applicants.
In practical terms, investors also need to factor in implied transaction costs. Each subscription requires a handling fee of NT$20 and a fee of NT$50 for mailing the lottery result notification. If you do not win, your subscription funds and the NT$50 postage fee will be refunded—so the NT$20 handling fee is a sunk cost.
In addition, Taiho Biotech (6467), currently trading in the OTC market before listing, has a reference price based on OTC quotes, where liquidity is relatively lower and price volatility can be higher. From the time of subscription and lottery to the official allocation and commencement of trading, there is still a time lag. Whether the stock price can maintain the current level at the time of formal listing remains uncertain. Investors should thoroughly assess risks and potential price volatility before participating.
How do you participate in a stock lottery?
For this Taiho Biotech (6467) public subscription, the tentative underwriting price is NT$105.6. Using recent OTC market conditions to estimate around NT$2401, winning one lot could mean potential profits of more than NT$130,000.
What’s worth noting is that the company’s existing shareholders have waived their preferential rights to subscribe for the new shares, and the entire issuance is handled by the securities underwriter for pre-listing public underwriting. Therefore, this release provides a total of 1,594 new share lots for public subscription. Although this increases the chance of winning a lot, the underlying reasons are also something to pay attention to.
The lottery process is simple. As long as you submit your application through your securities APP’s “Stock Lottery” section by 2:00 PM from 10/7 to 10/12, and deposit NT$105,670 into your delivery account before the payment/withdrawal date, you can participate. The lottery payment/withdrawal day is 10/13, and the results will be announced on 10/14.
This article Did You Win and Profit Over NT$130,000? Taiho Biotech (6467) Opens Public Subscription—What Should You Watch for When Applying for a Stock Lottery? First appeared on .
Did You Win and Profit Over NT$130,000? Taiho Biotech (6467) Opens Public Subscription—What Should You Watch for When Applying for a Stock Lottery?
Taiho Biotech (6467), a biotech company focused on developing new-formulation drugs, will open its public subscription from 10/7 to 10/12. Based on a tentative underwriting price of NT$105.6 and an estimated over-the-counter (OTC) market price of around NT$241, winning one lot could mean a potential profit of over NT$134,000, with a return rate as high as 127%. What is a stock lottery? And how do you participate? What does Taiho Biotech (6467) do?
Taiho Biotech (6467) was established in 2010. The company mainly focuses on R&D and patent licensing for “new formulations of drugs (505(b)(2)).” It has its own developed transdermal drug delivery system (TDS) technology platform. Its core business is centered on two major dosage forms: “oral dissolving films (ODF)” designed for patients with dysphagia, and “transdermal patches (Patch)” that provide long-lasting, stable drug delivery.
Taiho’s main product lines include the world’s first antithrombotic oral dissolving film (TAH3311 / Apixaban) improved specifically for populations with swallowing disorders, chemotherapy antiemetic patches, and medications related to the central nervous system. After being listed on Taiwan’s OTC market for years, Taiho Biotech has obtained approval from the Taiwan Stock Exchange and has officially kicked off pre-listing capital increase and public underwriting procedures.
What is a stock lottery?
The official term for a stock lottery is “public subscription.” It is a mechanism for companies to raise capital by issuing new shares to the public. When a company conducts an initial public offering (IPO) or a cash capital increase after listing, regulations require that a certain proportion of shares be allocated for public subscription.
Investors must submit an application through a broker’s trading platform and, on the designated payment/settlement day, ensure there is enough money in their delivery account for the subscription amount and related handling fees. If the total number of subscribers exceeds the number of share lots available for allocation, the Taiwan Stock Exchange will conduct a computer-based random lottery to ensure the allocation mechanism is fair and transparent.
What are the risks of a stock lottery?
For most investors, the key motivation for participating is the potential spread between the “underwriting price” and the “market price.” To attract market demand, lead underwriters typically offer the underwriting price at a discount relative to the market. However, participating in the subscription requires paying an opportunity cost—the funds are frozen. On the payment day after the subscription deadline, the full subscription amount will be deducted in advance and frozen for several trading days until the refund date for unsuccessful applicants.
In practical terms, investors also need to factor in implied transaction costs. Each subscription requires a handling fee of NT$20 and a fee of NT$50 for mailing the lottery result notification. If you do not win, your subscription funds and the NT$50 postage fee will be refunded—so the NT$20 handling fee is a sunk cost.
In addition, Taiho Biotech (6467), currently trading in the OTC market before listing, has a reference price based on OTC quotes, where liquidity is relatively lower and price volatility can be higher. From the time of subscription and lottery to the official allocation and commencement of trading, there is still a time lag. Whether the stock price can maintain the current level at the time of formal listing remains uncertain. Investors should thoroughly assess risks and potential price volatility before participating.
How do you participate in a stock lottery?
For this Taiho Biotech (6467) public subscription, the tentative underwriting price is NT$105.6. Using recent OTC market conditions to estimate around NT$2401, winning one lot could mean potential profits of more than NT$130,000.
What’s worth noting is that the company’s existing shareholders have waived their preferential rights to subscribe for the new shares, and the entire issuance is handled by the securities underwriter for pre-listing public underwriting. Therefore, this release provides a total of 1,594 new share lots for public subscription. Although this increases the chance of winning a lot, the underlying reasons are also something to pay attention to.
The lottery process is simple. As long as you submit your application through your securities APP’s “Stock Lottery” section by 2:00 PM from 10/7 to 10/12, and deposit NT$105,670 into your delivery account before the payment/withdrawal date, you can participate. The lottery payment/withdrawal day is 10/13, and the results will be announced on 10/14.
This article Did You Win and Profit Over NT$130,000? Taiho Biotech (6467) Opens Public Subscription—What Should You Watch for When Applying for a Stock Lottery? First appeared on .
